Immunome Ownership | Who Owns Immunome?

Overview Forecast RevenueFinancials Chart

Immunome Ownership Summary

Immunome is owned by 85.83% institutional investors, 16.77% insiders. Fmr is the largest institutional shareholder, holding 40.85% of IMNM shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 3.45% of its assets in Immunome shares.

IMNM Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Immunome	85.83%	16.77%	-2.60%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Fmr	4.21M	40.85%	$50.95M
Blackrock	3.76M	36.46%	$45.48M
Vanguard group	2.92M	28.34%	$35.35M
State street	2.36M	22.93%	$28.61M
Price t rowe associates inc /md/	2.02M	19.61%	$24.46M
Geode capital management	1.06M	10.31%	$12.86M
Redmile group	4.89M	8.16%	$59.16M
Ecor1 capital	3.88M	6.47%	$46.94M
T. rowe price investment management	3.88M	6.47%	$46.93M
Janus henderson group	3.16M	5.28%	$38.26M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Redmile group	4.89M	3.58%	$59.16M
Opaleye management	1.10M	3.05%	$13.34M
Ecor1 capital	3.88M	1.44%	$46.94M
Tang capital management	720.00K	0.89%	$8.71M
Avidity partners management lp	873.89K	0.45%	$10.57M
Sofinnova investments	655.68K	0.41%	$7.93M
Prosight management, lp	65.00K	0.24%	$786.50K
Vista private wealth partners.	39.12K	0.19%	$473.30K
Emfo	11.84K	0.13%	$143.20K
Titleist asset management	63.97K	0.12%	$774.00K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	3.76M	0.00%	2.93M
T. rowe price investment management	3.88M	0.03%	2.36M
State street	2.36M	0.00%	2.16M
Janus henderson group	3.16M	0.02%	1.63M
Marshall wace, llp	1.71M	0.03%	1.19M

Top Sellers

Holder	Shares	% Assets	Change
Point72 asset management	385.07K	0.01%	-1.26M
Vestal point capital, lp	-	-	-1.00M
Invesco	25.94K	0.00%	-599.15K
Farallon capital management	-	-	-594.00K
Millennium management	-	-	-465.29K

New Positions

Holder	Shares	% Assets	Change	Value
Opaleye management	1.10M	3.05%	1.10M	$13.34M
Nuveen asset management	299.29K	0.00%	299.29K	$3.62M
Adage capital partners gp	220.00K	0.00%	220.00K	$2.66M
Axa	179.69K	0.01%	179.69K	$2.17M
Rafferty asset management	116.05K	0.01%	116.05K	$1.40M

Sold Out

Holder	Change
Federated hermes	-335.00
Pacer advisors	-660.00
Kbc group nv	-1.01K
Simplex trading	-3.17K
Macquarie group	-3.52K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	121	5.22%	51,674,695	8.14%	85	1.35%	66	-13.16%	28	27.27%
Jun 30, 2024	115	7.48%	47,785,575	30.06%	79	2.12%	76	-12.64%	22	83.33%
Mar 31, 2024	107	81.36%	36,741,102	70.98%	61	4.77%	87	107.14%	12	100.00%
Dec 31, 2023	59	55.26%	21,488,187	810.23%	35	231.10%	42	180.00%	6	-40.00%
Sep 30, 2023	38	-5.00%	2,360,732	21.26%	3	37.33%	15	-	10	42.86%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price US Small-Cap Core Equity	2.07M	3.45%	792.36K
T. Rowe Price Small-Cap Stock	2.07M	3.45%	129.20K
Fidelity Growth Compy Commingled Pl O	1.79M	2.97%	-
Fidelity Growth Compy Commingled Pl S	1.80M	2.88%	10.54K
Vanguard Total Stock Mkt Idx Inv	1.64M	2.63%	2.26K
T. Rowe Price Health Sciences	1.53M	2.54%	127.28K
iShares Russell 2000 ETF	1.34M	2.14%	-3.00K
Fidelity Growth Company Fund	1.26M	2.02%	-2.67K
T. Rowe Price Instl Small-Cap Stock	1.03M	1.71%	68.50K
T. Rowe Price U.S. SC Core Eq Tr-Z	1.03M	1.71%	455.51K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 22, 2024	SIEGALL CLAY B	President and CEO	Buy	$331.92K
Nov 21, 2024	SIEGALL CLAY B	President and CEO	Buy	$630.26K
Nov 21, 2024	Lechleider Robert	Chief Medical Officer	Buy	$149.80K
Nov 21, 2024	Tsai Philip	Chief Technology Officer	Buy	$198.03K
Sep 19, 2024	Rosett Max	Chief Financial Officer	Sell	$230.22K

Insider Transactions Trends

Date	Buy	Sell
2024 Q3	1	2
2024 Q2	3	-
2024 Q1	-	-
2023 Q4	2	-
2023 Q2	-	-

IMNM Ownership FAQ

Who Owns Immunome?

Immunome shareholders are primarily institutional investors at 85.83%, followed by 16.77% insiders and -2.60% retail investors. The average institutional ownership in Immunome's industry, Biotech Stocks , is 47.04%, which Immunome exceeds.

Who owns the most shares of Immunome?

Immunome’s largest shareholders are Fmr (4.21M shares, 40.85%), Blackrock (3.76M shares, 36.46%), and Vanguard group (2.92M shares, 28.34%). Together, they hold 105.65% of Immunome’s total shares outstanding.

Does Blackrock own Immunome?

Yes, BlackRock owns 36.46% of Immunome, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 45.48M$. In the last quarter, BlackRock increased its holdings by 2.93M shares, a 353.41% change.

Who is Immunome’s biggest shareholder by percentage of total assets invested?

Redmile group is Immunome’s biggest shareholder by percentage of total assets invested, with 3.58% of its assets in 4.89M Immunome shares, valued at 59.16M$.

Who is the top mutual fund holder of Immunome shares?

T. Rowe Price US Small-Cap Core Equity is the top mutual fund holder of Immunome shares, with 3.45% of its total shares outstanding invested in 2.07M Immunome shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools